Clinical trial
A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates
NCT00045630 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2003
- Completion date
- December 31, 2011
- Enrollment
- 77 (actual)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.
bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer